<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991756</url>
  </required_header>
  <id_info>
    <org_study_id>ALTURA-ELE-1</org_study_id>
    <nct_id>NCT01991756</nct_id>
  </id_info>
  <brief_title>Safety and Performance of Altura Endograft in Abdominal Aortic Aneurysm (AAA) Endovascular Repair</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>ELEVATE International: Kissing Endografts for Peripheral AAA Exclusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altura Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altura Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the acute safety of deploying and&#xD;
      implanting the Altura Endograft in the treatment of AAA in subjects who are candidates for&#xD;
      endovascular repair.&#xD;
&#xD;
      Secondary objectives are to evaluate the acute and longer-term safety and performance of the&#xD;
      Altura Endograft through 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary safety endpoint of the study is freedom from Major Adverse Events (MAE), a&#xD;
      composite endpoint consisting of death, stroke, paraplegia, myocardial infarction,&#xD;
      respiratory failure, renal failure, bowel ischemia and blood loss ≥ 1000 mL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from Major Adverse Events (MAE), a composite endpoint consisting of:&#xD;
Death&#xD;
Stroke&#xD;
Paraplegia&#xD;
Myocardial infarction&#xD;
Respiratory failure&#xD;
Renal failure&#xD;
Bowel ischemia&#xD;
Blood loss ≥ 1000 mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint</measure>
    <time_frame>30 days, 6 and 12 months and annually through 5 years</time_frame>
    <description>Major Adverse Events (MAE)&#xD;
Aneurysm-related death&#xD;
Type I and III endoleaks&#xD;
AAA rupture&#xD;
Re-intervention to correct Type I or Type III endoleaks, migration, occlusion, narrowing, stenosis, kinking or fracture</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary Performance Endpoint</measure>
    <time_frame>Procedurally, 30 days, 6 and 12 months and annually through 5 years</time_frame>
    <description>Acute Technical Success&#xD;
Longer-term Technical Success, defined as subjects having Acute Technical Success and no evidence of&#xD;
Migration (greater than or equal to 10 mm)&#xD;
Occlusion&#xD;
Clinical Success, defined as subjects having Acute Technical Success and no evidence of&#xD;
Type I or Type III endoleaks&#xD;
AAA rupture&#xD;
Re-intervention (surgical or endovascular) to correct Type I or Type III endoleaks, migration, occlusion, narrowing, stenosis, kinking or fracture.&#xD;
Change in aneurysm sac size diameter&#xD;
Absolute change (mm)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>AAA</arm_group_label>
    <description>Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Altura Endograft System</intervention_name>
    <description>Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.</description>
    <arm_group_label>AAA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease with suitable&#xD;
        aneurysm morphology for endovascular repair.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Understands and has signed an Informed Consent&#xD;
&#xD;
          -  Candidate for endovascular or open surgical repair of an infrarenal aortic or&#xD;
             aorto-iliac aneurysm&#xD;
&#xD;
          -  Abdominal aneurysm &gt; 45 mm or aneurysm growth of &gt; 10 mm/year&#xD;
&#xD;
          -  Abdominal aneurysm neck angulation ≤ 60 degrees&#xD;
&#xD;
          -  Infrarenal non-aneurysmal neck 15 mm&#xD;
&#xD;
          -  Infrarenal non-aneurysmal neck diameter between 18 and 28 mm, inclusive&#xD;
&#xD;
          -  Iliac artery landing zone 15 mm in length&#xD;
&#xD;
          -  Iliac artery landing zone diameter between 8 and 18 mm, inclusive&#xD;
&#xD;
          -  Patent iliac and femoral arteries, access vessels, size and morphology, to allow&#xD;
             endovascular access of a minimum 14 Fr introducer sheath and catheter&#xD;
&#xD;
          -  Ability to preserve at least one hypogastric artery&#xD;
&#xD;
          -  Life expectancy &gt; one year&#xD;
&#xD;
          -  American Society of Anesthesiology (ASA) grade 1 through 3, inclusive&#xD;
&#xD;
          -  Able and willing to comply with follow-up visits at 30 days, 6 and 12 months and&#xD;
             annually through 5 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  An acutely ruptured, leaking or emergent aneurysm&#xD;
&#xD;
          -  An aortic dissection (Type A or B)&#xD;
&#xD;
          -  A mycotic, infected or inflammatory aneurysm&#xD;
&#xD;
          -  A thoracic, suprarenal or juxtarenal aneurysm&#xD;
&#xD;
          -  Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm or an&#xD;
             aorto-iliac aneurysm&#xD;
&#xD;
          -  Severe iliac artery tortuosity&#xD;
&#xD;
          -  Thrombus, calcification and/or plaque that may complicate sealing&#xD;
&#xD;
          -  Evidence or history of intracranial bleeding or aneurysm, myocardial infarction or&#xD;
             stroke within the past 3 months&#xD;
&#xD;
          -  Current angina or other active cardiac condition such as congestive heart failure,&#xD;
             untreated or worsening atrial arrhythmia, ventricular arrhythmia or valvular disease&#xD;
&#xD;
          -  Had or plans to have an unrelated major surgical or interventional procedure within 1&#xD;
             month before or after implantation of the study device&#xD;
&#xD;
          -  Significant (&gt;80%) diameter renal artery stenosis which could not be readily treated&#xD;
&#xD;
          -  Known sensitivity or allergy to nitinol or polyester&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to anticoagulation or contrast media that&#xD;
             is not amenable to pre-treatment&#xD;
&#xD;
          -  Contraindication to antiplatelet, anticoagulant or thrombolytic therapy;&#xD;
&#xD;
          -  Coagulopathy or uncontrolled bleeding disorder&#xD;
&#xD;
          -  History of heparin-induced thrombocytopenia (HIT)&#xD;
&#xD;
          -  Clinically and morbidly obese such that the required imaging would be prevented&#xD;
&#xD;
          -  Connective tissue disease (e.g., Marfan's or Ehlers-Danlos syndromes)&#xD;
&#xD;
          -  Currently on dialysis or has compromised renal function as reflected by a serum&#xD;
             creatinine &gt;2.0 mg/dL&#xD;
&#xD;
          -  Compromised hepatic function&#xD;
&#xD;
          -  Active infection at the time of the index procedure&#xD;
&#xD;
          -  End-stage chronic obstructive pulmonary disorder (COPD)&#xD;
&#xD;
          -  Religious, cultural or other objections to the receipt of blood or blood products&#xD;
&#xD;
          -  Participating in another research study involving an investigational device or drug&#xD;
             which may potentially affect study results&#xD;
&#xD;
          -  Other medical, social or psychological problems that, in the opinion of the&#xD;
             Investigator, preclude them from receiving this treatment and the procedures and&#xD;
             evaluations pre- and post-treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park-Krenkenhaus Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniklink</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Center</name>
      <address>
        <city>Hamburg-Eppendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park-Krankenhaus Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Bonifatius Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abdominal Aortic Aneurysms</keyword>
  <keyword>AAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

